Rezultati - Mat D. Davis

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia

    Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia od Hubert H. Fernandez, David Stamler, Mat D. Davis, Stewart A. Factor, Robert A. Hauser, Joohi Jimenez‐Shahed, William G. Ondo, L. Fredrik Jarskog, Scott W. Woods, Danny Bega, Mark S. LeDoux, David Shprecher, Karen E. Anderson

    Izdano 2019
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  2. 2
    Randomized controlled trial of deutetrabenazine for tardive dyskinesia

    Randomized controlled trial of deutetrabenazine for tardive dyskinesia od Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser, Joohi Jimenez‐Shahed, William G. Ondo, L. Fredrik Jarskog, Herbert Y. Meltzer, Scott W. Woods, Danny Bega, Mark S. LeDoux, David Shprecher, Charles H. Davis, Mat D. Davis, David Stamler, Karen E. Anderson

    Izdano 2017
    Polni tekst Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  3. 3
    Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals

    Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals od Reisa A. Sperling, Keith A. Johnson, P. Murali Doraiswamy, Eric M. Reiman, Adam Fleisher, Marwan N. Sabbagh, Carl Sadowsky, Alan Carpenter, Mat D. Davis, Ming‐Chi Lu, Matthew Flitter, Abhinay D. Joshi, Christopher M. Clark, Michael Grundman, Mark A. Mintun, Daniel Skovronsky, Michael J. Pontecorvo

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:
  4. 4
    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability

    The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability od Nicholas G. LaRocca, Lynn D. Hudson, Richard A. Rudick, Dagmar Amtmann, Laura J. Balcer, Ralph H. B. Benedict, Robert Bermel, Ih Chang, Nancy D. Chiaravalloti, Peter Chin, Jeffrey A. Cohen, Gary Cutter, Mat D. Davis, John DeLuca, Peter Feys, Gordon Francis, Myla Goldman, Emily Hartley, Raj Kapoor, Fred Lublin, Gary Lundstrom, Paul M. Matthews, Nancy E. Mayo, Richard C. Meibach, Deborah Miller, Robert W. Motl, Ellen M. Mowry, Rob Naismith, Jon Neville, Jennifer Panagoulias, Michael Panzara, Glenn Phillips, Ann Robbins, Matthew Sidovar, Kathryn E. Smith, Bjørn Sperling, Bernard M.J. Uitdehaag, Jerry Weaver

    Izdano 2017
    Polni tekst Polni tekst
    Revisão
    Dodaj v priljubljene
    Shranjeno v:
  5. 5
    Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline

    Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline od P. Murali Doraiswamy, Reisa A. Sperling, Robert E. Coleman, Keith A. Johnson, Eric M. Reiman, Mat D. Davis, Michael Grundman, Marwan N. Sabbagh, Carl Sadowsky, Adam Fleisher, Alan Carpenter, Christopher M. Clark, Abhinay D. Joshi, Mark A. Mintun, Daniel Skovronsky, Michael J. Pontecorvo, Ranjan Duara, Marwan N. Sabbagh, Geoffrey L. Ahern, Richard Holub, Mildred V. Farmer, Beth Safirstein, Gustavo Alva, Crystal Flynn Longmire, George Jewell, Keith A. Johnson, Ron Korn, Eric M. Reiman, Jeanette Wendt, Dean F. Wong, P. Murali Doraiswamy, RE Coleman, Michael D. Devous, Danna Jennings, Michael W. Weiner, Cynthia Murphy, Karel D. Kovnat, Jeff D. Williamson, Carl Sadowsky

    Izdano 2012
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: